ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors
dc.contributor.author | O'Connor, Joseph J. | |
dc.contributor.author | Ferraris, Dana | |
dc.contributor.author | Fehr, Anthony R. | |
dc.date.accessioned | 2024-06-03T18:02:31Z | |
dc.date.available | 2024-06-03T18:02:31Z | |
dc.date.issued | 2023-10-07 | |
dc.identifier.citation | O'Connor JJ, Ferraris D, Fehr AR. An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors. Pathogens. 2023 Oct 7;12(10):1221. doi: 10.3390/pathogens12101221. PMID: 37887737; PMCID: PMC10610136 | en_US |
dc.identifier.uri | https://hdl.handle.net/1808/35090 | |
dc.description.abstract | Non-structural protein 3 (nsp3) from all coronaviruses (CoVs) contains a conserved macrodomain, known as Mac1, that has been proposed as a potential therapeutic target for CoVs due to its critical role in viral pathogenesis. Mac1 is an ADP-ribose binding protein and ADP-ribosylhydrolase that promotes replication and blocks IFN responses, though the precise mechanisms it uses to carry out these functions remain unknown. Over the past 3 years following the onset of COVID-19, several groups have used high-throughput screening with multiple assays and chemical modifications to create unique chemical inhibitors of the SARS-CoV-2 Mac1 protein. Here, we summarize the current efforts to identify selective and potent inhibitors of SARS-CoV-2 Mac1. | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Copyright © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Macrodomain | en_US |
dc.subject | Mac1 | en_US |
dc.subject | ADP-ribosylation | en_US |
dc.subject | Inhibitors | en_US |
dc.subject | ADP-ribosylhydrolase | en_US |
dc.title | An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors | en_US |
dc.type | Article | en_US |
kusw.kuauthor | O'Connor, Joseph J. | |
kusw.kudepartment | Department of Molecular Biosciences | en_US |
dc.identifier.doi | 10.3390/pathogens12101221 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0001-5791-5939 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0003-1560-1573 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC10610136 | en_US |
dc.rights.accessrights | openAccess | en_US |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: Copyright © 2023 by the authors.
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).